Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.5K citations · Full text

WHO Handbook for Reporting Results of Cancer Treatment

M K Palmer · British Journal of Cancer · 1982 · 2.2K citations · Full text

Medicine, Cancer Management, Outcomes Research +4

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas, Reinhard Dummer, Igor Puzanov et al. · Cell · 2017 · 1.4K citations · Full text

Tumor Immunology, Anti-pd-1 Immunotherapy, Autoimmune Disease +10

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

Binlei Liu, Max Robinson, Z-Q Han et al. · Gene Therapy · 2003 · 783 citations

Herpes Simplex Virus, Immunology, Pathology +7

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Jason Chesney, Igor Puzanov, Frances A. Collichio et al. · Journal of Clinical Oncology · 2017 · 604 citations · Full text